Vitamin D and cardiorenal diseases

7th International Congress of Cardionephrology KARNEF (2025) [pp. 19-26]

AUTHOR(S) / АУТОР(И): Sebastjan Bevc , Tadej Petreski, Luka Varda, Nejc Piko, Robert Ekart, Radovan Hojs

Download Full Pdf   

DOI: 10.46793/KARNEF25.019B

ABSTRACT / САЖЕТАК:

Vitamin D is a crucial fat-soluble compound primarily involved in maintaining calcium-phosphate balance and promoting bone health. In recent years, its broader physiological roles, particularly in cardiovascular (CV) and kidney function, have garnered significant interest. Deficiency in vitamin D is a widespread issue, affecting a large portion of the global population, and is associated with various health problems, including CV disease. Research suggests adequate vitamin D levels help preserve vascular function, reduce inflammation and fibrosis, and potentially protect against hypertension, atherosclerosis, and albuminuria. Observational studies have consistently reported that low vitamin D levels are linked to an increased risk of heart disease, stroke, and high blood pressure. While supplementation is generally safe at recommended levels, further investigations are needed to clarify its role in CV risk reduction. This article examines the impact of vitamin D on the heart, blood vessels, and kidneys.

KEYWORDS / КЉУЧНЕ РЕЧИ:

REFERENCES / ЛИТЕРАТУРА:

  • Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81.
  • Latic N, Erben RG. Vitamin D and Cardiovascular Disease, with Emphasis on Hypertension, Atherosclerosis, and Heart Failure. Int J Mol Sci. 2020;21(18).
  • Pludowski P. Supplementing Vitamin D in Different Patient Groups to Reduce Deficiency. Nutrients. 2023;15(17).
  • Shah VP, Nayfeh T, Alsawaf Y, Saadi S, Farah M, Zhu Y, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D. J Clin Endocrinol Metab. 2024;109(8):1961-74.
  • Cortese F, Costantino MF, Luzi G, Di Marino S, Giordano P, Monitillo F. Vitamin D and cardiovascular disease risk. A literature overview. Mol Biol Rep. 2022;49(9):8925-42.
  • Cosentino N, Campodonico J, Milazzo V, De Metrio M, Brambilla M, Camera M, et al. Vitamin D and Cardiovascular Disease: Current Evidence and Future Perspectives. Nutrients. 2021;13(10).
  • Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-38.
  • Kunadian V, Ford GA, Bawamia B, Qiu W, Manson JE. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am Heart J. 2014;167(3):283-91.
  • Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11.
  • Kong SY, Jung E, Hwang SS, Ro YS, Shin SD, Cha KC, et al. Circulating Vitamin D Level and Risk of Sudden Cardiac Death and Cardiovascular Mortality: A Dose-Response Meta-Analysis of Prospective Studies. J Korean Med Sci. 2023;38(33):e260.
  • Darabian S, Rattanasompattikul M, Hatamizadeh P, Bunnapradist S, Budoff MJ, Kovesdy CP, et al. Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease. Kidney Research and Clinical Practice. 2012;31(1):12-25.
  • Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. Journal of the American college of cardiology. 2008;52(19):1527-39.
  • Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. Journal of the American College of Cardiology. 2009;53(23):2129-40.
  • Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Primary care: Clinics in office practice. 2008;35(2):329-44.
  • Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Journal of the American Society of Nephrology. 2005;16(6):1788-93.
  • Zhao G, Ford ES, Li C. Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among US adults without physician-diagnosed diabetes: NHANES, 2003–2006. Diabetes care. 2010;33(2):344-7.
  • Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1, 25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. Journal of cardiovascular pharmacology. 2008;51(6):559-64.
  • Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen Y-S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences. 2007;104(43):16810-5.
  • Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. American journal of kidney diseases. 2009;53(3):408-16.
  • Jean G, Souberbielle J-C, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrology Dialysis Transplantation. 2009;24(12):3799-805.
  • Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. The American journal of clinical nutrition. 2006;83(4):754-9.
  • Baker LR, Abrams SL, Roe CJ, Faugere M-C, Fanti P, Subayti Y, et al. 1, 25 (OH) 2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney international. 1989;35(2):661-9.
  • Wolf M, Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. The Journal of steroid biochemistry and molecular biology. 2007;103(3-5):487-90.
  • De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet. 2010;376(9752):1543-51.
  • de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol. 2013;24(11):1863-71.
  • Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New England Journal of Medicine. 2003;349(5):446-56.
  • Pan S, Yang K, Shang Y, Yu R, Liu L, Jin J, et al. Effect of regulated vitamin D increase on vascular markers in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases. 2024;34(1):33-44.
  • Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart failure reviews. 2012;17:211-20.
  • Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44.
  • Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, et al. Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. JAMA Cardiol. 2019;4(8):765-76.
  • Janousek J, Pilarova V, Macakova K, Nomura A, Veiga-Matos J, Silva DDD, et al. Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. Crit Rev Clin Lab Sci. 2022;59(8):517-54.